CELG News 83.13 07/18/2014 04:49:12 Celgene Corp (CELG)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celgene Corp (CELG) 83.13 $CELG

SmarTrend Watching for Potential Rebound in Shares of Celgene After 3.39% Loss
Comtex SmarTrend(R) - Thu Jul 17, 4:35PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $82.90 to a high of $86.19. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $85.60 on volume of 5.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Celgene Set to Possibly Rebound After Yesterday's Selloff of 3.39%
Comtex SmarTrend(R) - Thu Jul 17, 4:34PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $82.90 to a high of $86.19. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $85.60 on volume of 5.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Midday Glance: Biotechnology companies
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:

Celgene Shares Up 15.5% Since SmarTrend's Buy Recommendation (CELG)
Comtex SmarTrend(R) - Thu Jul 17, 11:13AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 3 months, Celgene has returned 15.53% as of today's recent price of $85.42.

Cramer: The Tell of When to Sell
at The Street - Thu Jul 17, 9:40AM CDT
If you're worried about these moves, it's time to cash out.

Early Glance: Biotechnology companies
AP - Thu Jul 17, 9:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 16, 8:49AM CDT
Focus last week remained on AbbVie's (ABBV) attempts to acquire Shire (SHPG) - the company came back with a revised offer which could very well be accepted by Shire.

Will Johnson & Johnson (JNJ) Beat this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 3:45PM CDT
Johnson & Johnson (JNJ) is scheduled to report second quarter 2014 results before the opening bell on Jul 15.

Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 10:30AM CDT
Two members of the U.S. Senate Finance Committee issued a letter to Gilead asking it to justify the high price of Sovaldi.

Stocks Close Higher As Biotech, Internet Stocks Gain
at Investor's Business Daily - Fri Jul 11, 3:40PM CDT
Tech stocks outperformed Friday in an otherwise quiet, low-volume session. The Nasdaq, up most of the day, rose 0.4%. The Dow Jones industrial average climbed 0.2% and the S&P 500 edged up 0.1% after erasing modest losses. Volume fell 15% on the NYSE...

Oncolytics Up on Patient Enrolment Completion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 2:00PM CDT
Oncolytics Biotech Inc. (ONCY) finished enrolling patients in a phase II study (OSU-10045) on its oncology candidate, Reolysin.

Are These the Best Big Biotech Stocks for Your Portfolio?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 10, 4:00PM CDT
Gilead Sciences  has had a banner year. Sovaldi, the hepatitis c cure, was a huge seller in its first full quarter on the market, netting $2.3 billion and blowing away analyst expectations. Celgene  has had a more mixed experience this year,...

Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 10:30AM CDT
Celgene's (CELG) Otezla failed to meet the primary endpoint in a late stage study.

Celgene Up 17.1% Since SmarTrend Uptrend Call (CELG)
Comtex SmarTrend(R) - Thu Jul 10, 9:55AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 2 months, Celgene has returned 17.08% as of today's recent price of $86.56.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TransDigm Surges Ahead with Strong Q4 and FY Results

Updated Category News Views 54

TransDigm's Impressive Performance in Fiscal 2026 Here's a company that's really kicking it up a notch—TransDigm Group (NYSE:TDG) just reported some solid fourth-quarter numbers that scream growth. Net sales soared to $2,988 million, marking a 23% hike from last year's fourth quarter of $2,437 million. That's a cool $551 million leap, quite the party for shareholders....

Continue Reading
Ebix Relaunches A.D.A.M. SmartCare Platform for Clinicians

Updated Category News Views 118

Revolutionizing Patient Education with SmartCare When you're in the thick of things, juggling a half-dozen patients with different needs all in a day’s work, you want your tools to be as fast and straightforward as a greasy spoon diner breakfast—simple, satisfying, and utterly dependable. And Ebix is betting they've cooked up just the recipe for that with their...

Continue Reading
HSF Opens Scholar Program to All Ethnicities

Updated Category News Views 339

Redefining Eligibility for Inclusive Progress Picture this: the landscape of educational support shifting towards inclusivity. The Hispanic Scholarship Fund (HSF), long a champion for Hispanic educational advancement, is taking a bold step by opening its doors wider. From January 2027, the HSF Scholar Program will embrace students of all backgrounds, a massive leap away...

Continue Reading
Hansa Bolsters Financials with SERB Deal, Eyes Growth

Updated Category News Views 17

Financial Gains and Strategic Shifts Oh, here we go again—another quarterly report from Hansa Biopharma, and this one’s got some meat on its bones. They’ve sparked up their financial engine with a hefty €115 million licensing deal with SERB, which is a real shot in the arm. As any investor worth their salt would see, this isn’t just about piling cash. It's...

Continue Reading
Ampace Showcases Safety-First Battery Tech for AI Data Centers

Updated Category News Views 27

PU200's Debut: Making Safety and Space Work in Tandem Ever noticed how safety's become the name of the game for data center operations? Powered by the influx of AI, these digital fortresses crave robust power backup, and Ampace’s stepping in with their PU200 UPS battery solution at Data Centre World Paris 2026. Showing off at Hall 5, Booth M65, Ampace's bringing to the...

Continue Reading
Entenmann's Packs Seasonal Joy into Limited-Time Treats

Updated Category News Views 52

Winter Treats Stepping into the Limelight Another year, another holiday season descended upon us—the calorie indulgence is real, folks. There’s something criminally comforting about these recurring flavors, especially when Entenmann’s and Little Bites decide it’s time to drop some trademark nostalgia into the frosty mix. Pop these limited-edition sweets on your...

Continue Reading
Wood Partners Commences on 301-Unit Alta Meadowlands

Updated Category News Views 103

Planting the Seeds for Alta Meadowlands It's all systems go for Wood Partners and GrayCo as they kick off construction on Alta Meadowlands in Hillsborough, North Carolina. Now, this isn't just another boxy warehouse masquerading as an apartment complex. We're talking a real commitment to shaking up the local real estate scene—a 301-unit community right in the...

Continue Reading
Envista's $430M Senior Notes: A Market Move Decoded

Updated Category News Views 114

Envista on the Move with $430M Notes Ever feel like the market's a bit like a rollercoaster with no brakes? That's kind of where we're at with Envista Holdings Corporation (NYSE: NVST) rolling out this new financial play. They just priced a hefty $430 million in Senior Notes at a solid 6.250% due 2033. In terms of the investment world, that's a pretty big splash. The...

Continue Reading
AEWIN Unveils Powerful Servers with AMD EPYC Chips

Updated Category News Views 83

AEWIN's Bold Move in Server Tech Hang onto your hats, folks, 'cause AEWIN Technologies just took its server game to a whole new level. During the AMD in Depth: EPYC "Venice" event in Las Vegas, AEWIN, nestled neatly under the Qisda Group umbrella, hit the market with hardware that's bound to turn heads—both literally and figuratively. With their latest server offerings...

Continue Reading
MIT Study: Reinforced Masonry Slashes Hurricane Damage

Updated Category News Views 87

Building Smarter: Concrete vs. The Storm Hurricanes are nature’s wrecking balls, and if there’s one thing the latest MIT study tosses on the table, it’s that reinforced concrete masonry isn't just holding its ground—it's changing the game. You see, when Hurricane Irma swung through Florida, it left a clear message written in the rubble: smarter building means...

Continue Reading

Top 5 Most Recently Viewed Articles

Rivian's Strategic Expansion with Volkswagen Boosts EV Journey

Updated Category News Views 300

Rivian and Volkswagen Strengthen Their Collaboration Recent discussions between Volkswagen and Rivian highlight the potential for an expanded partnership that may greatly impact the electric vehicle (EV) industry. Volkswagen’s CEO, Oliver Blume, recently commented on the exciting opportunities presented by this collaboration, which focuses on leveraging shared resources...

Continue Reading
Investigation Announced for TransMedics Group, Inc. Investors

Updated Category News Views 199

Investigation into TransMedics Group, Inc. Announced The Rosen Law Firm, a prominent legal practice dedicated to defending investor rights, has recently initiated an investigation regarding potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX). This move follows serious allegations that the company may have provided materially...

Continue Reading
Significant Regulatory Challenges for Telix Pharmaceuticals Unfold

Updated Category News Views 145

Regulatory Challenges for Telix Pharmaceuticals Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is currently navigating through difficult regulatory waters, prompting investors to rethink their positions. A recent reminder issued by the well-regarded national law firm Hagens Berman highlights the mounting issues surrounding the company's prostate cancer drug, TLX591, and its...

Continue Reading
Invest Green Acquisition Corp Secures $172.5 Million IPO Success

Updated Category News Views 233

Invest Green Acquisition Corporation Celebrates IPO Achievement Invest Green Acquisition Corporation is thrilled to announce the successful closing of its initial public offering, which raised an impressive $172.5 million. This achievement represents the sale of 17,250,000 units at a price of $10.00 per unit. The offering included the exercise of an overallotment option...

Continue Reading
Anticipated Growth in Automotive Suspension Market by 2034

Updated Category News Views 135

Significant Growth Anticipated in the Automotive Suspension Sector The global automotive suspension shock absorber market is forecasted to grow remarkably from USD 31.5 billion to USD 45.2 billion over the next decade, with an average annual growth rate of 4.0%. This surge reflects evolving consumer priorities towards enhanced comfort, safety, and advanced vehicle...

Continue Reading